Cagrilintide
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Cagrilintide?
Novo Nordisk's long-acting amylin analog, on a different receptor pathway from GLP-1 entirely, signaling satiety through the brainstem.
Studied alone at 11.5% weight loss over 68 weeks in REDEFINE 1, and as the second half of CagriSema.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Cagrilintide comes up on this site
On GLP Watchdog, Cagrilintide comes up in 2 research articles and 3 FDA warning letters. Browse the FDA warning letters.
Research that discusses it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers